Ocugen Announces OCU400—Modifier Gene Therapy

[VUBot]

MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) OCGN, a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at…

#malvern #ocugeninc #ocugen #benjaminbakall #phd #phoenix #seattle #wa #bla #maa

Continue reading...